Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0XR7C
|
|||
Former ID |
DIB014060
|
|||
Drug Name |
YM-598
|
|||
Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [1] | |
Company |
Astellas
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C24H20KN5O5S
|
|||
Canonical SMILES |
COC1=CC=CC=C1OC2=C(N=C(N=C2OC)C3=NC=CC=N3)[N-]S(=O)(=O)C=CC4=CC=CC=C4.[K+]
|
|||
InChI |
1S/C24H20N5O5S.K/c1-32-18-11-6-7-12-19(18)34-20-21(29-35(30,31)16-13-17-9-4-3-5-10-17)27-23(28-24(20)33-2)22-25-14-8-15-26-22;/h3-16H,1-2H3;/q-1;+1/b16-13+;
|
|||
InChIKey |
WOPWEXSDEXIRNG-ZUQRMPMESA-N
|
|||
CAS Number |
CAS 342005-82-7
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Endothelin A receptor (EDNRA) | Target Info | Antagonist | [2] |
KEGG Pathway | Calcium signaling pathway | |||
cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Vascular smooth muscle contraction | ||||
Renin secretion | ||||
Pathways in cancer | ||||
NetPath Pathway | IL4 Signaling Pathway | |||
Panther Pathway | Endothelin signaling pathway | |||
Pathway Interaction Database | Endothelins | |||
EGFR-dependent Endothelin signaling events | ||||
Reactome | Peptide ligand-binding receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | Prostaglandin Synthesis and Regulation | |||
GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Peptide GPCRs | ||||
Endothelin Pathways | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00050297) YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer. U.S. National Institutes of Health. | |||
REF 2 | Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol. 2011 May; 163(2): 220-233. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.